In 2018 was created Sherpa Venture Capital, which is appeared as VC. The venture was found in Asia in China. The leading representative office of defined VC is situated in the Beijing.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular fund investment industries, there are Medical Device, Clinical Trials. Among the most popular portfolio startups of the fund, we may highlight EpimAb Biotherapeutics, Singleron Biotechnologies, Immunochina. The fund has exact preference in a number of founders of portfolio startups.
The fund is constantly included in 7-12 investment rounds annually. Considering the real fund results, this VC is 60 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2019.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Sherpa Venture Capital, startups are often financed by Trend Investment Group, Thiel Capital, ShengJing360. The meaningful sponsors for the fund in investment in the same round are Legend Capital, Hillhouse Capital Group, WuXi AppTec.
We also calculated 2 valuable employees in our database.
Funds with similar focus
|3taps||California, San Francisco, United States|
|Edison Electric Institute||District of Columbia, United States, Washington|
|Escala Partners||Australia, Melbourne, Victoria|
|Founders & Fools||Norway, Oslo|
|Great Wall Motors||China, Hebei, Hebei|
|Huaxin Lianzhong Touzi||Beijing, Beijing, China|
|Shining Capital||China, Hong Kong, Hong Kong Island|
|Sichuan Hongbo Equity Investment Fund Management||China, Gansu, Sichuan|
|$50M||02 Sep 2022||Shanghai, Shanghai, China|
Fountain Medical Development
|$150M||04 Jul 2022||New York, New York, United States|
|$43M||20 Jun 2022||Haidian, Beijing, China|
|$15M||14 Jun 2022||Xiamen, China|
|$23M||16 May 2022||Suzhou, Jiangsu, China|
|12 May 2022||Shanghai, China|
|$46M||11 Apr 2022||Nanjing, Jiangsu, China|
|$30M||14 Mar 2022||Pudong, Shandong, China|
|16 Dec 2021||Suzhou, Jiangsu, China|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.